{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:09:55Z","timestamp":1783019395751,"version":"3.54.6"},"update-to":[{"DOI":"10.1002\/14651858.cd014383","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000}}],"reference-count":149,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014383.pub2","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T19:25:49Z","timestamp":1661887549000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia"],"prefix":"10.1002","volume":"2022","author":[{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rodolico","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Psychiatry Unit; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto T","family":"Samara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine; University of Thessaly; Larisa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf-Peter","family":"Hansen","sequence":"additional","affiliation":[{"name":"BASTA - B\u00fcndnis f\u00fcr psychisch erkrankte Menschen; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Salomone","sequence":"additional","affiliation":[{"name":"Biomedical and Biotechnological Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Aguglia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Psychiatry Unit; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfelice","family":"Cutrufelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Psychiatry Unit; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Bauer","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"},{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty; University of Augsburg; Augsburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lio","family":"Baeckers","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.4088\/JCP.14m09321","article-title":"Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"77","author":"Borlido","year":"2016","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0002|cit2","unstructured":"Antipsychotic polypharmacy in schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00493233"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.psychres.2017.09.050","article-title":"Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used?","volume":"263","author":"Constantine","year":"2018","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.schres.2015.05.038","article-title":"The risks and bene\ufb01ts of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial","volume":"166","author":"Constantine","year":"2015","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD014383.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0006|cit6","unstructured":"Switching medication to treat schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00044655"},{"issue":"12","key":"10.1002\/14651858.CD014383.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.jpsychires.2013.08.024","article-title":"Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients","volume":"47","author":"Hori","year":"2013","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0008|cit8","unstructured":"Polypharmacy in clozapine-resistant schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00918021"},{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4081\/mi.2012.e1","article-title":"Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment","volume":"4","author":"Repo-Tiihonen","year":"2012","journal-title":"Mental Illness"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0447.2010.01553.x","article-title":"Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients","volume":"122","author":"Baandrup","year":"2010","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0011|cit11","unstructured":"Antipsychotic polypharmacy: prevalence, background and consequences clinicaltrials.gov\/ct2\/show\/NCT00541398"},{"issue":"2","key":"10.1002\/14651858.CD014383.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00735817","article-title":"Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramine in parkinsonism","volume":"47","author":"Corsini","year":"1976","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0013|cit13","first-page":"348","article-title":"Heterogeneity among youth with serious mental illness in intensive care management and post-discharge polypharmacy use","volume":"25","author":"DosReis","year":"2016","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0014|cit14","unstructured":"Fricchione V Balletta G Addeo L Manna G Effectiveness of antipsychotic polypharmacy or monotherapy: real-world study outcomes 25th ECNP Congress; 2012 Oct 13-17; Vienna, Austria"},{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ebmh.10.1.15","article-title":"Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia","volume":"10","author":"Chaplin","year":"2007","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0016|cit16","unstructured":"Greenspan A Kosik-Gonzalez C Bossie C Zhu Y Gharabawi G Predictors of readiness to discharge among inpatients with schizophrenia 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY)"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0017|cit17","unstructured":"Greenspan A Kosik-Gonzalez C Bossie C Zhu Y McLemore J Gharabawi G Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA)"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0018|cit18","unstructured":"Greenspan A Kosik-Gonzalez C Moreau-Mallet V Bossie CA Rupnow MF Zhu Y Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study 18th European College of Neuropsychopharmacology Congress; 2005 Oct 22-26; Amsterdam, the Netherlands"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014383.pub2-BIB0019|cit19","first-page":"S503","article-title":"Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study","volume":"15","author":"Greenspan","year":"2005","journal-title":"European Neuropsychopharmacology"},{"issue":"1-3","key":"10.1002\/14651858.CD014383.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.schres.2006.03.027","article-title":"A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization","volume":"85","author":"Potkin","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0021|cit21","first-page":"501","article-title":"A placebo-controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia","volume":"31","author":"Potkin","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0022|cit22","unstructured":"Rupnow M Greenspan A Kosik-Gonzalez C Bossie C Zhu Y Gharabawi G Polypharmacy in schizophrenia: data from a randomized, double-blind study 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA)"},{"issue":"11","key":"10.1002\/14651858.CD014383.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1185\/030079907X233359","article-title":"Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder","volume":"23","author":"Rupnow","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1002\/14651858.CD014383.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1098-3015(10)63082-3","article-title":"Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine","volume":"8","author":"Rupnow","year":"2005","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0025|cit25","first-page":"550","article-title":"Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine","volume":"31","author":"Rupnow","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014383.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/S0924-977X(07)70237-7","article-title":"A randomized controlled trial of antipsychotic polypharmacy: clozapine plus risperidone","volume":"17","author":"Honer","year":"2007","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0028|cit28","unstructured":"International study of improving treatment for the most severely ill with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00272584"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JCP.0b013e3181f28dff","article-title":"A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia","volume":"30","author":"Lin","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014383.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1016\/S0924-977X(09)70369-4","article-title":"A randomized, double-blind, comparison of risperidone versus risperidone plus haloperidol treatment in schizophrenia","volume":"19","author":"Lin","year":"2009","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD014383.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1017\/S1092852919000877","article-title":"Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia - a pooled analysis","volume":"24","author":"Lin","year":"2019","journal-title":"CNS Spectrums"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0032|cit32","unstructured":"Comparison of the efficacy and safety of risperidone versus risperidone plus low dose of haloperidol in the treatment of schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00998608"},{"issue":"6","key":"10.1002\/14651858.CD014383.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1017\/S1092852919000877","article-title":"Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia - a pooled analysis","volume":"24","author":"Lin","year":"2019","journal-title":"CNS Spectrums"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/YIC.0b013e3283633a83","article-title":"Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study","volume":"28","author":"Lin","year":"2013","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0035|cit35","unstructured":"A randomized, double-blind, comparison of the efficacy and safety of amisulpride versus low-dose amisulpride plus low-dose sulpiride in the treatment of schizophrenia clinicaltrials.gov\/ct2\/show\/NCT01615185"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.psychres.2018.02.058","article-title":"Early prediction of olanzapine-induced weight gain for schizophrenia patients","volume":"263","author":"Lin","year":"2018","journal-title":"Psychiatry Research"},{"issue":"6","key":"10.1002\/14651858.CD014383.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1017\/S1092852919000877","article-title":"Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia - a pooled analysis","volume":"24","author":"Lin","year":"2019","journal-title":"CNS Spectrums"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2017.01.004","article-title":"A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia","volume":"185","author":"Lin","year":"2017","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0039|cit39","unstructured":"Olanzapine vs. low-dose olanzapine plus trifluoperazine clinicaltrials.gov\/ct2\/show\/NCT02704962"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0040|cit40","unstructured":"Nicotine receptor density and response to nicotine patch: Pt 2 extended treatment clinicaltrials.gov\/ct2\/show\/NCT02676375"},{"issue":"4","key":"10.1002\/14651858.CD014383.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/YIC.0000000000000125","article-title":"Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy","volume":"31","author":"Alphs","year":"2016","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0042|cit42","unstructured":"Bilder RM Pandina G Lasser R Rodriguez S Turkoz I Prosser J Cognitive and functional improvement with long-acting risperidone treatment 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0043|cit43","unstructured":"Bossie C Gharabawi G Rodriguez SC Dragotta K Simpson GM Remission of schizophrenia symptoms associated with functional improvement 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0044|cit44","unstructured":"Gharabawi G Bossie C Bouhours P Turkoz I Gearhart N Kujawa M Insight in schizophrenia: results from a 12-month, double-blind study insight in schizophrenia: results from a 12 month double blind study 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0045|cit45","unstructured":"Gharabawi G Bossie C Turkoz I Bouhours P Kujawa M Does insight predict functioning and quality of life in schizophrenia? Results from a 12-month, double-blind study 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland"},{"issue":"12","key":"10.1002\/14651858.CD014383.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/NMD.0b013e31815c1982","article-title":"The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable","volume":"195","author":"Gharabawi","year":"2007","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014383.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S0924-977X(06)70477-1","article-title":"Insight in schizophrenia: clinical correlates and relationship to functioning","volume":"16","author":"Gharabawi","year":"2006","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1176\/ajp.2006.163.5.938a","article-title":"New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol","volume":"163","author":"Gharabawi","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0049|cit49","unstructured":"Harvey P Pandina G Bilder R Rodriguez S Turkoz I Gharabawi G Cognitive and functional improvement with long-acting risperidone treatment 44th Annual Meeting of the American College of Neuro-Psychopharmacology; 2005 Dec 11-15; Waikoloa (HI)"},{"issue":"2","key":"10.1002\/14651858.CD014383.pub2-BIB0050|cit50","first-page":"438","article-title":"Factors associated with improved psychosocial functioning in patients with schizophrenia","volume":"33","author":"Kujawa","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0051|cit51","unstructured":"Kujawa M Bossie C Turkoz I Simpson G Gharabawi G Remission of schizophrenia symptoms associated with functional improvement 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0052|cit52","unstructured":"Lasser R Pandina G Bilder R Harvey P Rodriguez S Turkoz I Cognitive and functional improvement with long-acting risperidone treatment 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA)"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0053|cit53","first-page":"492","article-title":"Optimization of long-acting risperidone for maintenance therapy in schizophrenia","volume":"31","author":"Lasser","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0054|cit54","first-page":"494","article-title":"Maintenance therapy with long-acting risperidone: functioning and quality of life in patients with schizophrenia or schizoaffective disorder","volume":"31","author":"Locklear","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0055|cit55","unstructured":"MacFadden W Bossie C Turkoz I Diekamp B Ibach B Haskins JT Effect of long-acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients 26th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2008 Jul 13-17; Munich, Germany"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0056|cit56","unstructured":"MacFadden W Bossie C Turkoz I Dorson P Haskins T Effect of long-acting injectable risperidone on clinical outcomes in stable schizophrenia patients with early illness 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington (DC)"},{"issue":"2","key":"10.1002\/14651858.CD014383.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/YIC.0b013e3283347cbf","article-title":"Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia","volume":"25","author":"MacFadden","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014383.pub2-BIB0058|cit58","first-page":"S497","article-title":"Improved cognition observed in patients with schizophrenia with risperidone long-acting injectable","volume":"15","author":"Mattys","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0059|cit59","unstructured":"A 52-wk prospective, randomized, double-blind, multicenter study of relapse following transition from oral antipsychotic medication to 2 different doses (25 or 50 mg every 2 wks) of risperidone long-acting microspheres (Risperdal CONSTA) in adults with schizophrenia or schizoaffective disorder clinicaltrials.gov\/ct2\/show\/NCT00297388"},{"issue":"2-3","key":"10.1002\/14651858.CD014383.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.schres.2012.11.031","article-title":"Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder","volume":"143","author":"Pandina","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0061|cit61","unstructured":"Pandina GJ Gharabawi G Rodriguez S Lasser R The relationship between cognitive measures and functional outcomes in schizophrenia 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY)"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0062|cit62","unstructured":"Rodriguez SC Kujawa M Turkoz I Rediess S Gharabawi G Long-acting risperidone treatment following antipsychotic polypharmacy 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0063|cit63","unstructured":"Rodriguez SC Lasser R Turkoz I Mahableshwarkar AR Gharabawi GM Chung H Optimized long-acting risperidone maintenance therapy 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA)"},{"issue":"8","key":"10.1002\/14651858.CD014383.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4088\/JCP.v67n0804","article-title":"A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder","volume":"67","author":"Simpson","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0065|cit65","unstructured":"Turkoz I Lasser R Rodriguez SC Locklear JC Mahableshwarkar AR Gharabawi GM Functioning and quality of life during long-acting risperidone maintenance treatment 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014383.pub2-BIB0066|cit66","first-page":"S227","article-title":"Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine","volume":"29","author":"Stahl","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0067|cit67","first-page":"169","article-title":"A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics","volume":"1","author":"Sukegawa","year":"2008","journal-title":"Tottori Journal of Clinical Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1744-859X-6-13","article-title":"QTc and psychopharmacs: are there any differences between monotherapy and polytherapy","volume":"6","author":"Sumic","year":"2007","journal-title":"Annals of General Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0069|cit69","unstructured":"Thompson A Barley M Sullivan SA Strange SO Moore L Sipos A A pragmatic cluster randomised controlled trial of a complex ward-based intervention on antipsychotic polypharmacy prescribing in adult psychiatric inpatient wards 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Jan 1; Davos, Switzerland"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1017\/S003329170700147X","article-title":"The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial","volume":"38","author":"Thompson","year":"2008","journal-title":"Psychological Medicine\u00a0"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1016\/j.eurpsy.2016.01.2287","article-title":"Pharmacotherapy of acute psychotic states: the reason for benzodiazepines and valproic acid augmentation","volume":"33","author":"Veraksa","year":"2016","journal-title":"European Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e1002798","DOI":"10.1371\/journal.pmed.1002798","article-title":"Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: a randomised controlled trial (DREAMeR-study)","volume":"16","author":"Verdoorn","year":"2019","journal-title":"PLOS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-244X-14-103","article-title":"Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan","volume":"14","author":"Sukegawa","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0074|cit74","unstructured":"The clinical study to correct multiple and large amount of administering to antipsychotic safely and effectively center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000005391"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ijnp\/pyu016","article-title":"Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method","volume":"18","author":"Yamanouchi","year":"2015","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/WNF.0000000000000175","article-title":"Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia","volume":"39","author":"Yoon","year":"2016","journal-title":"Clinical Neuropharmacology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD014383.pub2-BIB0077|cit77","first-page":"S35","article-title":"Concurrent treatment with typical and atypical antipsychotics: double trouble","volume":"267","author":"Shakir","year":"2017","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"7066","key":"10.1002\/14651858.CD014383.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"62","author":"Andreasen","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","article-title":"Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study","volume":"170","author":"Andreasen","year":"2013","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0081|cit81","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)","author":"APA 1987 American Psychiatric Association","year":"1987"},{"issue":"12","key":"10.1002\/14651858.CD014383.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009780.pub3","article-title":"Implementation of treatment guidelines for specialist mental health care","author":"Bighelli","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD014383.pub2-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014384","article-title":"Antipsychotic dose reduction compared to dose continuation for people with schizophrenia","author":"Bighelli","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7108","key":"10.1002\/14651858.CD014383.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD014383.pub2-BIB0085|cit85","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2147\/NDT.S83546","article-title":"Employment and the associated impact on quality of life in people diagnosed with schizophrenia","volume":"11","author":"Bouwmans","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Buchanan","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0088|cit88","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa"},{"issue":"6","key":"10.1002\/14651858.CD014383.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD014383.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD014383.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0099|cit99","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"9","key":"10.1002\/14651858.CD014383.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0101|cit101","volume-title":"Clinical Global Impression Scale (CGI). ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD014383.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0104|cit104","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"4","key":"10.1002\/14651858.CD014383.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorthoj","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","article-title":"Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia","volume":"68","author":"Ho","year":"2011","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1440-1819.2007.01725.x","article-title":"Brief Assessment of Cognition in Schizophrenia: validation of the Japanese version","volume":"61","author":"Kaneda","year":"2007","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0110|cit110","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/9781119536604.ch4","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2019"},{"issue":"11","key":"10.1002\/14651858.CD014383.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD014383.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub2","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD014383.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.schres.2019.05.030","article-title":"Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: a systematic review and meta-analysis","volume":"209","author":"Matsui","year":"2019","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiological Reviews"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-244X-11-118","article-title":"Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for life-style effects? A cross-sectional study","volume":"11","author":"Misawa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"e0195687","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: a reexamination","volume":"62","author":"Palmer","year":"2005","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.euroneuro.2014.01.014","article-title":"Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales","volume":"24","author":"Patel","year":"2014","journal-title":"European Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD014383.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD014383.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/acps.12332","article-title":"Risk factors for suicide in schizophrenia: systematic review and clinical recommendations","volume":"130","author":"Popovic","year":"2014","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0128|cit128","unstructured":"R: a language and environment for statistical computing R Foundation for Statistical Computing 2017"},{"issue":"3","key":"10.1002\/14651858.CD014383.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0130|cit130","unstructured":"Review Manager Web Cochrane"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/ebmental-2020-300151","article-title":"Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies","volume":"24","author":"Roberts","year":"2021","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD014383.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD014383.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/schbul\/sby095","article-title":"How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials","volume":"45","author":"Samara","year":"2019","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD014383.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"sgaa061","DOI":"10.1093\/schizbullopen\/sgaa061","article-title":"Cochrane Schizophrenia Group's Study-Based Register of Randomized Controlled Trials: development and content analysis","volume":"1","author":"Shokraneh","year":"2020","journal-title":"Schizophrenia Bulletin Open"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1111\/hir.12366","article-title":"Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis","author":"Shokraneh","journal-title":"Health Information and Libraries Journal"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD014383.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.schres.2012.10.015","article-title":"Interventions to reduce antipsychotic polypharmacy: a systematic review","volume":"143","author":"Tani","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/acps.12913","article-title":"Mortality in schizophrenia: 30-year nationwide follow-up study","volume":"138","author":"Tanskanen","year":"2018","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD014383.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/JCP.0b013e3181bf4ea3","article-title":"D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia","volume":"29","author":"Uchida","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD014383.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"10 pt 1","key":"10.1002\/14651858.CD014383.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.neubiorev.2012.09.006","article-title":"Confounders of excessive brain volume loss in schizophrenia","volume":"37","author":"Haren","year":"2013","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014383.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"i5396","DOI":"10.1136\/bmj.i5396","article-title":"80% of China's clinical trial data are fraudulent, investigation finds","volume":"355","author":"Woodhead","year":"2016","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD014383.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD014383.pub2-BIB0149|cit149","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014383","article-title":"Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia\u00a0","author":"Bighelli","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T08:47:54Z","timestamp":1686818874000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014383.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":149,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014383.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}